ConCallIQ
Go Pro
Home › Aarti Pharmalabs › Margin Trend

Aarti Pharmalabs Margin Trend — Quarter by Quarter

Aarti Pharmalabs's EBITDA margin moved from 24.6% in Q1 FY26 to 19.0% in Q4 FY26 across 3 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.

EBITDA Margin by Quarter

QuarterEBITDA Margin (%)YoY Change
Q4 FY2619.0%-340 bps
Q3 FY2624.0%-530 bps
Q1 FY2624.6%+720 bps

What management said about ebitda margin

G

Q4 FY26 · Revenue and EBITDA growth of 15-18% over next 3-4 years

Management targets 15-18% CAGR in both revenue and EBITDA for the medium term, driven by capacity ramp-up and CDMO growth.

G

Q3 FY26 · FY26 EBITDA flat to marginal growth

Management expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali delays and API softness.

G

Q1 FY26 · Standalone EBITDA growth of 12-15% for FY26

Management reiterated standalone EBITDA growth guidance of 12-15% for FY26, supported by margin expansion and CDMO ramp-up.